Peter Rahmer - 27 Jun 2023 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Title: Chief Corporate Development Officer
Signature
/s/ Brian Adams, as attorney-in-fact
Issuer symbol
RLAY
Transactions as of
27 Jun 2023
Net transactions value
-$2,957
Form type
4
Filing time
28 Jun 2023, 17:12:40 UTC
Previous filing
01 Jun 2023
Next filing
31 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Sale $2,957 -244 -0.08% $12.12 318,160 27 Jun 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 991 shares of restricted stock units ("RSUs") on June 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F2 Includes 290,341 shares underlying RSUs.

Remarks:

Title: Chief Corporate Development Officer